PharmacoEconomics & Outcomes News 480 - 18 Jun 2005 Access to HIV/AIDS therapy widens down under Patients with HIV infections who live in New Zealand will soon have greater access to the fixed combination antiretroviral agent lopinavir/ritonavir [Kaletra], courtesy of the country’s drug funding agency Pharmac. 1 The decision, due to take effect on 1 July this year, is expected to see the number of people who receive Kaletra double immediately, and will cost an estimated $NZ1.2 million * over 5 years. In addition, the agency is also extending the use of antiretrovirals to help prevent mother-to-child transmission of HIV infections. Both decisions have been designed to bring treatment for patients with HIV/AIDS into line with international guidelines, says to Pharmac’s chief executive Wayne McNee. Pharmac has also decided to continue funding two brandname versions of salbutamol, Salamol and Ventolin, at the same level for the next 2 years. 2 * New Zealand dollars 1. PHARMAC. Two steps forward for HIV treatment. Media Release : 12 Jun 2005. Available from: URL: http://www.pharmac.govt.nz. 2. PHARMAC. Two salbutamol brands to remain funded -- Pharmac. Media Release : 8 Jun 2005. Available from: URL: http://www.pharmac.govt.nz. 800999359 1 PharmacoEconomics & Outcomes News 18 Jun 2005 No. 480 1173-5503/10/0480-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Access to HIV/AIDS therapy widens down under

Download PDF Report

Upload
dangxuyen
View
217
Download
1

Embed Size (px)

Citation preview

PharmacoEconomics & Outcomes News 480 - 18 Jun 2005

Access to HIV/AIDS therapy widensdown under

Patients with HIV infections who live in New Zealandwill soon have greater access to the fixed combinationantiretroviral agent lopinavir/ritonavir [Kaletra], courtesyof the country’s drug funding agency Pharmac.1

The decision, due to take effect on 1 July this year, isexpected to see the number of people who receiveKaletra double immediately, and will cost an estimated$NZ1.2 million* over 5 years. In addition, the agency isalso extending the use of antiretrovirals to help preventmother-to-child transmission of HIV infections. Bothdecisions have been designed to bring treatment forpatients with HIV/AIDS into line with internationalguidelines, says to Pharmac’s chief executive WayneMcNee.

Pharmac has also decided to continue funding twobrandname versions of salbutamol, Salamol andVentolin, at the same level for the next 2 years.2

* New Zealand dollars

1. PHARMAC. Two steps forward for HIV treatment. Media Release : 12 Jun2005. Available from: URL: http://www.pharmac.govt.nz.

2. PHARMAC. Two salbutamol brands to remain funded -- Pharmac. MediaRelease : 8 Jun 2005. Available from: URL: http://www.pharmac.govt.nz.

800999359